Is high HDL cholesterol always good?

Abstract

Because of the obvious negative relation between high-density lipoprotein (HDL) cholesterol and cardiovascular disease and the substantial residual risk of this disease even during treatment with high-dose statin there has been an urgent need to investigate the possible therapeutic benefit of increasing HDL. Even if treatment with nicotinic acid with its marked HDL-increasing effect has been encouraging, there is no evidence so far that specific increase of HDL cholesterol results in less cardiovascular disease. Treatment with the cholesterol ester transfer protein (CETP) inhibitor and HDL-increasing drug torcetrapib resulted in increased risk of cardiovascular disease. These negative results were followed by a lively discussion regarding the possible benefit of HDL-increasing treatment in general and CETP inhibition in particular. Suggested possible causes for the negative outcome by torcetrapib treatment are off-target non-CETP-related effect of this particular inhibitor, inability of very high blood HDL cholesterol levels to protect, induction of dysfunctional HDL, and direct atherogenic effect of CETP inhibition. It is concluded that still today little is known about the effect of specific therapeutic elevation of HDL cholesterol, particularly so through CETP inhibition on cardiovascular risk. New interventional studies on this therapeutic principle are welcomed and under way.

• Anacetrapib
• atherosclerosis
• cholesterol ester transfer protein (CETP)
• CETP inhibition
• coronary heart disease (CHD)
• CHD prevention
• dalcetrapib
• high-density lipoprotein (HDL)
• torcetrapib

Acknowledgements

The author is indebted to Dr Gregory Schwartz for critical review of the manuscript.

Declaration of interest: Dr Olsson has received consultation fees or support for clinical trials from Artery Therapeutics, AstraZeneca, Genzyme, Karobio, MSD, Pfizer, Roche, Sanofi, and Takeda. The author alone is responsible for the content and writing of the paper.